Expert: Professor Jorge Cortes Georgia Cancer Centre, Augusta (USA)

Program:
Overview of significant clinical aspects presented during the meeting, including:

• Frontline therapy studies (03:14)
  
  • Final results of the TIGER trial: Nilotinib vs. Interferon + Nilotinib (03:41)
  • Results of the FASCINATION trial: Asciminib + Nilotinib (06:04)
  • Asciminib single agent study (08:55)
• Mutational abnormalities in genes other than BCR-ABL (10:44)
  • Clonal hematopoiesis mutants at the time of TFR (11:24)
  • Presence of somatic mutations prior to TFR (13:04)
• Debate: Is genomic screening essential prior to frontline therapy? (14:01)
• Treatment-free remission studies (16:12)
  • Final analysis of the EURO-SKI study (16:19)
  • Study on TFR in children (17:05)
• Studies with patients outside of current recommendations (17:38)

Q&A Session can be found at the end of the biological overview

If you have any questions or comments to the speaker, please email info@cml-foundation.org.